Stuttgart - Delayed Quote EUR

Seres Therapeutics Inc (1S9.SG)

0.8408

+0.0048

+(0.57%)

At close: January 24 at 5:43:39 PM GMT+1

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Company’s previously announced sale of its VOWST business to Société des Produits Nestlé S.A (SPN, and with certain of its affiliates, collectively, Nestlé Health Science). This installment payment was expected as Seres is fulfilling its transition obligations. As

GlobeNewswire 10 days ago

MCRB
Seres announces new translational biomarker results from SER-155 Phase 1b study

Seres Therapeutics (MCRB) announced new translational biomarker results for exploratory endpoints from its SER-155 Phase 1b placebo-controlled study in patients undergoing allogenic stem cell transplantation. “Following SER-155 administration, there was a statistically significant decrease in fecal albumin, an established biomarker of epithelial barrier integrity, and a positive impact on biomarkers of systemic inflammation and immune homeostasis, in both cases as compared to placebo. These resu

TipRanks 16 days ago

MCRB
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barrier integrity and decreased systemic inflammatory biomarkers compared to placebo; data support the broader potential of Seres’ live biotherapeutics to target inflammatory and immune diseases SER-155 clinical results accepted for 2025 TANDEM Meeting oral presentation in Best Abstracts in Infectious Diseases New SER-155 payer resear

GlobeNewswire 17 days ago

MCRB
The past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitable

It's not possible to invest over long periods without making some bad investments. But really big losses can really...

Simply Wall St. last month

MCRB
Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference

Seres Therapeutics (MCRB) announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Eric Shaff, President and CEO, will present a corporate overview on January 16, 2025 at 7:30 a.m. PT. Seres will highlight its plans to advance its biotherapeutics pipeline, focusing on SER-155, the Company’s lead program. The Company recently announced that SER-155 received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing all

TipRanks last month

MCRB
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Eric Shaff, President and Chief Executive Officer, will present a corporate overview on January 16, 2025 at 7:30 a.m. PT. Seres will highlight its plans to advance its biotherapeutics pipeline, focusing on SER-155, the Company’s lead program. The Company recently

GlobeNewswire last month

MCRB
Seres’ SER-155 gains breakthrough status for BSIs reduction

A live biotherapeutic, SER-155 secured fast track status from the FDA in December 2023.

Pharmaceutical Technology last month

MCRB
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo Breakthrough Therapy meeting with FDA on next study of SER-155 in allo-HSCT expected in Q1 2025 Seres seeking SER-155 strategic partnership to accelerate next study in allo-HSCT and expand to multiple target populations CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the C

GlobeNewswire last month

MCRB
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 4:30 p.m. ET. A live webcast of the chat will be accessible through the “Events and Presentations” tab on the “Investors and News” section of the Company’s website at www.seresther

GlobeNewswire 2 months ago

MCRB
Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023)

Seres Therapeutics ( NASDAQ:MCRB ) Third Quarter 2024 Results Key Financial Results Net loss: US$51.0m (loss widened by...

Simply Wall St. 2 months ago

MCRB
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...

Seres Therapeutics Inc (MCRB) reports promising clinical results and strategic financial maneuvers, despite facing increased net losses and operational uncertainties.

GuruFocus.com 2 months ago

MCRB
Seres Therapeutics: Q3 Earnings Snapshot

CAMBRIDGE, Mass. AP) — Seres Therapeutics Inc. MCRB) on Wednesday reported third-quarter earnings of $88.8 million.

Associated Press Finance 2 months ago

MCRB
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

SER-155 Phase 1b placebo-controlled clinical results demonstrated significant reduction in both bacterial bloodstream infections and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as compared to placebo, through day 100 post allo-HSCT Financial position strengthened following completion of VOWST™ sale; based on existing cash, projected 2025 deal economics and current operating plans, Seres expects to fund operations into Q4 2025 Seeking SER-155 strategic partner

GlobeNewswire 2 months ago

MCRB
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 13, 2024 at 8:30 a.m. ET to discuss third quarter 2024 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 5051385. To join the live webca

GlobeNewswire 2 months ago

MCRB
Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 12% of holdings value

Key Insights Seres Therapeutics' significant retail investors ownership suggests that the key decisions are influenced...

Simply Wall St. 3 months ago

MCRB
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable patient populations at high risk of life-threatening bacterial infections Cash received at completion, along with anticipated future deal payments, extends runway into Q4 2025 CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics

GlobeNewswire 3 months ago

MCRB
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

CAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that its stockholders voted to approve the previously announced proposed sale of the Company’s VOWST business to Société des Produits Nestlé S.A. Seres will file a Current Report on Form 8-K with the SEC which details the voting results. The transaction is expected to close on September 30, 2024, subject to the satisfact

GlobeNewswire 3 months ago

MCRB
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that the Company, will participate in the Cantor Global Healthcare Conference and Eric Shaff, President and Chief Executive Officer, will represent Seres in a presentation on September 18, 2024 at 3:05 p.m. ET. A video webcast of the presentation will be available under the “Events and Presentations” tab on the “Investors and News” section of Seres

GlobeNewswire 4 months ago

MCRB
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as compared to placebo through day 100 post HSCT Demonstrated generally well tolerated safety profile and confirmed drug bacteria strain engraftment; no treatment-related serious adverse events Company to seek Breakthrough Therapy designation from the FDA, given the high unmet medical need associate

GlobeNewswire 4 months ago

MCRB
After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)

The heavy selling pressure might have exhausted for Seres Therapeutics (MCRB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks 4 months ago

MCRB

Performance Overview

Return	1S9.SG	S&P 500
YTD	+1.72%	+3.29%
1-Year	-24.25%	+25.42%
3-Year	-87.54%	+38.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Seres Therapeutics Inc (1S9.SG)

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Seres announces new translational biomarker results from SER-155 Phase 1b study

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

The past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitable

Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Seres’ SER-155 gains breakthrough status for BSIs reduction

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023)

Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...

Seres Therapeutics: Q3 Earnings Snapshot

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 12% of holdings value

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)

Performance Overview